

JANUS HENDERSON CAPITAL FUNDS PLC – JANUS HENDERSON GLOBAL LIFE SCIENCES FUND

A2 USD ISIN IE0009355771

Key investment risks:

- The Fund's investments in equities are subject to equity market risk due to fluctuation of securities values.
- Investments in the Fund involve general investment, currency, hedging, economic, political, policy, foreign exchange, liquidity, tax, legal, regulatory, securities financing transactions related and small/ mid-capitalisation companies related risks. In extreme market conditions, you may lose your entire investment.
- The Fund may invest in financial derivatives instruments for investment and efficient portfolio management purposes. This may involve counterparty, liquidity, leverage, volatility, valuation, over-the-counter transaction, credit, currency, index, settlement default and interest risks; and the Fund may suffer total or substantial losses.
- The Fund's investments are concentrated in companies (may include small/ mid capitalization companies) with life sciences orientation and may be more volatile.
- Investors should not only base on this document alone to make investment decisions and should read the offering documents including the risk factors for further details.

Investment Objective and Strategy


The Fund aims to provide capital growth over the long term. The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Performance (%)

Returns	1 Month	3 Month	YTD	1 Year	3 Year	5 Year	10 Year	Since inception
A2 USD (Net)	-0.37	-2.71	5.39	0.74	18.27	52.65	80.51	441.90
Index	1.12	1.04	7.59	3.63	15.82	58.13	104.23	512.49
Sector	-0.62	-0.66	5.17	1.32	3.14	27.11	53.10	324.07

Cumulative growth - USD

28 Feb 2015 — 28 Feb 2025



Calendar year	2024	2023	2022	2021	2020
A2 USD (Net)	1.72	5.44	-4.35	4.72	23.41
Index	1.13	3.76	-5.41	19.80	13.52
Sector	-0.97	2.67	-13.91	7.12	20.53

Fund details

Inception date	31 March 2000
Total net assets	\$4.00bn
Asset class	Equities
Domicile	Ireland
Structure	Irish Investment Company
Base currency	USD
Index	MSCI World Health Care Index
Morningstar sector	Sector Equity Healthcare
SFDR category	Article 8

In accordance with the Sustainable Finance Disclosure Regulation, the Fund is classified as Article 8 and promotes, among other characteristics, environmental and/or social characteristics, and invests in companies with good governance practices.

Share class information

Inception date	31 March 2000
NAV (USD)	54.19
Distribution type	Accumulation
Distribution frequency	N/A
Currency	USD
Minimum initial investment	2,500

Portfolio management

Andy Acker, CFA	Manager since 2007
Daniel Lyons, Ph.D., CFA	Manager since 2023

Ratings

Overall Morningstar Rating™ ★★★★★
As of 28/02/2025

For more information, refer to page 3.

Performance is on a net of fees basis, with gross income reinvested. Source: at 28/02/25. © 2025 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. **Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.** Please note index returns are net of tax.

Characteristics

Annual turnover (1yr trailing)	32.56%
Weighted average market cap	215.71bn
Price-to-book ratio	5.10
Price-to-earnings ratio	19.51

Risk statistics (3 years)

	Fund	Index
Beta	1.00	—
Standard deviation	14.55	13.84
Sharpe ratio	0.09	0.05
Tracking error	4.69	—

Top holdings (%)

	Fund
Eli Lilly & Co	10.10
UnitedHealth Group Inc	5.99
AstraZeneca PLC	4.00
Novo Nordisk A/S	3.40
Johnson & Johnson	3.30
Abbott Laboratories	3.18
Boston Scientific Corp	3.09
Sanofi SA	2.88
Amgen Inc	2.77
AbbVie Inc	2.74
Total	41.45

References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.

Market capitalisation of equity holdings (%)

	Fund	Index
Over \$100B	59.13	67.46
\$50B to \$100B	4.78	10.80
\$10B to \$50B	13.49	19.91
\$5B to \$10B	8.86	1.67
\$1B to \$5B	11.86	0.08
\$500M to \$1B	0.71	—
\$100M to \$250M	0.11	—
Under \$100M	0.04	—
N/A	0.89	0.08

Sector allocation (%)

	Fund	Index
Pharmaceuticals	32.49	42.14
Biotechnology	31.31	14.66
Health Care Equipment	16.05	17.56
Managed Health Care	8.04	7.84
Life Sciences Tools & Services	5.15	7.86
Health Care Distributors	2.24	2.20
Health Care Supplies	2.24	2.97
Health Care Facilities	1.14	0.94
Health Care Services	1.00	3.21
Application Software	0.13	—

Top countries/regions (%)

	Fund	Index
United States	79.37	72.12
Denmark	4.83	4.18
United Kingdom	4.75	4.75
Switzerland	3.66	7.83
France	2.88	3.01
Netherlands	2.15	0.27
China	0.90	—
Israel	0.79	0.24
Ireland	0.28	—
Japan	0.26	3.57

Regions (%)

	Fund	Index
North America	79.38	72.12
Europe	18.54	22.52
Asia/Pacific Ex Japan	0.90	1.55
Africa/Mideast	0.79	0.24
Japan	0.26	3.57

Codes

ISIN	IE0009355771
Bloomberg	JANGLA1
Cusip	G50110165
SEDOL	0935577

Fees & charges (%)

Maximum initial sales charge	5.00
Annual management charge (AMC)	1.50

Fund charges will impact the value of your investment. In particular, the ongoing charges applicable to each fund will dilute investment performance, particularly over time. For further explanation of charges please visit our Fund Charges page at www.janushenderson.com. Under some circumstances initial charges may apply. Please refer to the Prospectus for more details.

Additional fund information

Tax assumptions and reliefs depend upon an investor's particular circumstances and may be subject to change. Janus Henderson Global Life Sciences Fund's investment objective and policy were changed effective 29 November 2024. Please note: due to rounding the figures in the holdings breakdowns may not add up to 100%. This is an Irish Investment Company regulated by the Central Bank of Ireland. Note that any differences among portfolio securities currencies, share class currencies and costs to be paid or represented in currencies other than your home currency will expose you to currency risk. Costs and returns may increase or decrease as a result of currency and exchange rate fluctuations. To obtain our prospectus and any additional information please visit our website on: www.janushenderson.com. A short-term trading fee may be applied upon exiting the fund as per the prospectus. Investment into the fund will acquire units/shares of the fund itself and not the underlying assets owned by the fund. Cash balances and exposures are based on settled and unsettled trades as at the reporting date.

Source for fund ratings/awards

Overall Morningstar Rating™ is a measure of a fund's risk-adjusted return, relative to similar funds. Fund share classes are rated from 1 to 5 stars, with the best performers receiving 5 stars and the worst performers receiving a single star. Overall Morningstar Rating™ is shown for Janus Henderson share classes achieving a rating of 4 or 5. For the Morningstar Rating category, refer to page 1 Morningstar sector. Ratings should not be taken as a recommendation. For more detailed information about Morningstar Ratings, including its methodology, please go to <https://shareholders.morningstar.com/investor-relations/governance/Compliance--Disclosure/default.aspx>.

Glossary

Beta

Beta measures how a fund or security moves in relationship to the overall market. A market has a beta of 1. If the fund/security's beta is more than 1, it moves more than the market, while a beta lower than 1 means it moves to a lesser extent than the market. A negative beta could mean the fund/security moves in the opposite direction to the market.

Price-to-book (P/B) ratio

A financial ratio used to value a company's shares. It is calculated by dividing a company's market value (share price) by the book value of its equity (value of the company's assets on its balance sheet). A P/B value <1 can indicate a potentially undervalued company or a declining business. The higher the P/B ratio, the higher the premium the market is willing to pay for the company above the book (balance sheet) value of its assets.

Price-to-earnings (P/E) ratio

A popular ratio used to value a company's shares, compared to other stocks, or a benchmark index. It is calculated by dividing the current share price by its earnings per share.

Sharpe ratio

This measures a portfolio's risk-adjusted performance. A high Sharpe ratio indicates a better risk-adjusted return. The ratio is designed to measure how far a portfolio's return can be attributed to fund manager skill as opposed to excessive risk taking.

Standard deviation

A statistic that measures the variation or dispersion of a set of values/data. A low standard deviation shows the values tend to be close to the mean while a high standard deviation indicates the values are more spread out. In terms of valuing investments, standard deviation can provide a gauge of the historical volatility of an investment.

Tracking error

This measures how far a portfolio's actual performance differs from its benchmark index. The lower the number, the more closely it resembles the index.

Weighted average market cap

The average market capitalisation of a holding, weighted by the size of that position in a portfolio or index.

Offering documents
can be downloaded
here:



Janus Henderson
INVESTORS

FOR MORE INFORMATION PLEASE VISIT JANUSHENDERSON.COM

Issued in Hong Kong by Janus Henderson Investors Hong Kong Limited, licensed and regulated by the Securities and Futures Commission ("SFC"). This document has not been reviewed by the SFC. The content herein is produced for information purposes only and does not constitute investment advice or as an offer to sell, buy or a recommendation for any security. Janus Henderson Investors is not responsible for any unlawful distribution of this document to any third parties, in whole or in part, and do not make any warranties with regards to the results obtained from its use. In preparing this document, Janus Henderson Investors has reasonable belief to rely upon the accuracy and completeness of all information available from public sources. **Past performance does not predict future returns. Investing involves risk, including the possible loss of principal and fluctuation of value.**

Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds.

Investors are warned that they should only make their investments based on the most recent offering documents which contains information about fees, expenses and risks, which is available from appointed intermediaries, and which should be read carefully. An investment in the Fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. Investors are advised to consult your intermediary who will give you advice on the product suitability and help you determine how your investment would be consistent with your own investment objectives. The investment decisions are yours and an investment in the Fund may not be suitable for everyone. If in doubt, please contact your intermediary for clarification. Portfolio holdings are subject to change without notice.

© 2025 Morningstar. All Rights Reserved. CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiary entities. ©Janus Henderson Group plc.